Cargando…
Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge
Administration of influenza vaccines via the respiratory tract has potential benefits over conventional parenteral administration, inducing immunity directly at the site of influenza exposure as well as being needle free. In this study, we investigated the suitability of Advax™, a stable particulate...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier B.V.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7111335/ https://www.ncbi.nlm.nih.gov/pubmed/30218687 http://dx.doi.org/10.1016/j.jconrel.2018.09.006 |
_version_ | 1783513268113899520 |
---|---|
author | Tomar, Jasmine Patil, Harshad P. Bracho, Gustavo Tonnis, Wouter F. Frijlink, Henderik W. Petrovsky, Nikolai Vanbever, Rita Huckriede, Anke Hinrichs, Wouter L.J. |
author_facet | Tomar, Jasmine Patil, Harshad P. Bracho, Gustavo Tonnis, Wouter F. Frijlink, Henderik W. Petrovsky, Nikolai Vanbever, Rita Huckriede, Anke Hinrichs, Wouter L.J. |
author_sort | Tomar, Jasmine |
collection | PubMed |
description | Administration of influenza vaccines via the respiratory tract has potential benefits over conventional parenteral administration, inducing immunity directly at the site of influenza exposure as well as being needle free. In this study, we investigated the suitability of Advax™, a stable particulate polymorph of inulin, also referred to as delta inulin, as a mucosal adjuvant for whole inactivated influenza vaccine (WIV) administered either as a liquid or dry powder formulation. Spray freeze-drying produced Advax-adjuvanted WIV powder particles in a size range (1–5 μm) suitable for inhalation. The physical and biological characteristics of both WIV and Advax remained unaltered both by admixing WIV with Advax and by spray freeze drying. Upon intranasal or pulmonary immunization, both liquid and dry powder formulations containing Advax induced significantly higher systemic, mucosal and cellular immune responses than non-adjuvanted WIV formulations. Furthermore, pulmonary immunization with Advax-adjuvanted WIV led to robust memory B cell responses along with an increase of lung localization factors i.e. CXCR3, CD69, and CD103. A less pronounced but still positive effect of Advax was seen on memory T cell responses. In contrast to animals immunized with WIV alone, all animals pulmonary immunized with a single dose of Advax-adjuvanted WIV were fully protected with no visible clinical symptoms against a lethal dose of influenza virus. These data confirm that Advax is a potent mucosal adjuvant that boosts vaccine-induced humoral and cellular immune responses both in the lung and systemically with major positive effects on B-cell memory and complete protection against live virus. Hence, respiratory tract immunization, particularly via the lungs, with Advax-adjuvanted WIV formulation as a liquid or dry powder is a promising alternative to parenteral influenza vaccination. |
format | Online Article Text |
id | pubmed-7111335 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | The Authors. Published by Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71113352020-04-02 Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge Tomar, Jasmine Patil, Harshad P. Bracho, Gustavo Tonnis, Wouter F. Frijlink, Henderik W. Petrovsky, Nikolai Vanbever, Rita Huckriede, Anke Hinrichs, Wouter L.J. J Control Release Article Administration of influenza vaccines via the respiratory tract has potential benefits over conventional parenteral administration, inducing immunity directly at the site of influenza exposure as well as being needle free. In this study, we investigated the suitability of Advax™, a stable particulate polymorph of inulin, also referred to as delta inulin, as a mucosal adjuvant for whole inactivated influenza vaccine (WIV) administered either as a liquid or dry powder formulation. Spray freeze-drying produced Advax-adjuvanted WIV powder particles in a size range (1–5 μm) suitable for inhalation. The physical and biological characteristics of both WIV and Advax remained unaltered both by admixing WIV with Advax and by spray freeze drying. Upon intranasal or pulmonary immunization, both liquid and dry powder formulations containing Advax induced significantly higher systemic, mucosal and cellular immune responses than non-adjuvanted WIV formulations. Furthermore, pulmonary immunization with Advax-adjuvanted WIV led to robust memory B cell responses along with an increase of lung localization factors i.e. CXCR3, CD69, and CD103. A less pronounced but still positive effect of Advax was seen on memory T cell responses. In contrast to animals immunized with WIV alone, all animals pulmonary immunized with a single dose of Advax-adjuvanted WIV were fully protected with no visible clinical symptoms against a lethal dose of influenza virus. These data confirm that Advax is a potent mucosal adjuvant that boosts vaccine-induced humoral and cellular immune responses both in the lung and systemically with major positive effects on B-cell memory and complete protection against live virus. Hence, respiratory tract immunization, particularly via the lungs, with Advax-adjuvanted WIV formulation as a liquid or dry powder is a promising alternative to parenteral influenza vaccination. The Authors. Published by Elsevier B.V. 2018-10-28 2018-09-12 /pmc/articles/PMC7111335/ /pubmed/30218687 http://dx.doi.org/10.1016/j.jconrel.2018.09.006 Text en © 2018 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Tomar, Jasmine Patil, Harshad P. Bracho, Gustavo Tonnis, Wouter F. Frijlink, Henderik W. Petrovsky, Nikolai Vanbever, Rita Huckriede, Anke Hinrichs, Wouter L.J. Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge |
title | Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge |
title_full | Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge |
title_fullStr | Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge |
title_full_unstemmed | Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge |
title_short | Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge |
title_sort | advax augments b and t cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7111335/ https://www.ncbi.nlm.nih.gov/pubmed/30218687 http://dx.doi.org/10.1016/j.jconrel.2018.09.006 |
work_keys_str_mv | AT tomarjasmine advaxaugmentsbandtcellresponsesuponinfluenzavaccinationviatherespiratorytractandenablescompleteprotectionofmiceagainstlethalinfluenzaviruschallenge AT patilharshadp advaxaugmentsbandtcellresponsesuponinfluenzavaccinationviatherespiratorytractandenablescompleteprotectionofmiceagainstlethalinfluenzaviruschallenge AT brachogustavo advaxaugmentsbandtcellresponsesuponinfluenzavaccinationviatherespiratorytractandenablescompleteprotectionofmiceagainstlethalinfluenzaviruschallenge AT tonniswouterf advaxaugmentsbandtcellresponsesuponinfluenzavaccinationviatherespiratorytractandenablescompleteprotectionofmiceagainstlethalinfluenzaviruschallenge AT frijlinkhenderikw advaxaugmentsbandtcellresponsesuponinfluenzavaccinationviatherespiratorytractandenablescompleteprotectionofmiceagainstlethalinfluenzaviruschallenge AT petrovskynikolai advaxaugmentsbandtcellresponsesuponinfluenzavaccinationviatherespiratorytractandenablescompleteprotectionofmiceagainstlethalinfluenzaviruschallenge AT vanbeverrita advaxaugmentsbandtcellresponsesuponinfluenzavaccinationviatherespiratorytractandenablescompleteprotectionofmiceagainstlethalinfluenzaviruschallenge AT huckriedeanke advaxaugmentsbandtcellresponsesuponinfluenzavaccinationviatherespiratorytractandenablescompleteprotectionofmiceagainstlethalinfluenzaviruschallenge AT hinrichswouterlj advaxaugmentsbandtcellresponsesuponinfluenzavaccinationviatherespiratorytractandenablescompleteprotectionofmiceagainstlethalinfluenzaviruschallenge |